In this study, researchers looked at the adoption and use of bevacizumab in order to identify opportunities to increase use of high-value therapies.
Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.
The Food and Drug Administration approved the first generic for everolimus, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.
The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.
The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.
Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of “rare” cases of immunotherapy-related adverse events.
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.
New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer.
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.